Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29069468 | 0.98 | DPP4 (0.38) | DPP4DPP8DPP7BTKHCAR2 | |
| SCHEMBL29279154 | 0.98 | DPP4 (0.38) | DPP4DPP8DPP7BTKHCAR2 | |
| SCHEMBL17645894 | 0.98 | DPP4 (0.38) | DPP4DPP8DPP7BTKHCAR2 | |
| SCHEMBL19449365 | 0.83 | DPP4 (0.39) | DPP4DPP8DPP7BTKKDM4E | |
| SCHEMBL23984196 | 0.82 | DPP4 (0.34) | DPP4DPP8DPP7 | |
| SCHEMBL29279127 | 0.82 | DPP4 (0.38) | DPP4DPP8DPP7BTKKDM4E | |
| SCHEMBL22659519 | 0.82 | DPP4 (0.40) | DPP4DPP8DPP7BTKKDM4E | |
| SCHEMBL2678063 | 0.82 | DPP4 (0.38) | DPP4DPP8DPP7BTKKDM4E | |
| Lithium Ion SCHEMBL23304121 | 0.80 | DPP4 (0.37) | DPP4DPP8DPP7BTK | |
| Potassium Ion SCHEMBL20532715 | 0.80 | DPP4 (0.37) | DPP4DPP8DPP7BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389004-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | EMD Serono Research and Development Institute, Inc. | 2022-12-08 | — | — | US | claimed |
| EP-3843847-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | Merck Patent GmbH (DE) | 2021-07-07 | — | — | EP | claimed |
| CN-112930213-A | Fused imidazopyridines as reversible inhibitors of Bruton's Tyrosine Kinase (BTK) | 默克专利有限公司 | 2021-06-08 | — | — | CN | claimed |
| WO-2020043638-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | MERCK PATENT GMBH (DE) | 2020-03-05 | — | — | WO | claimed |
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BIOGEN MA INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | MERCK PATENT GMBH (DE) | 2025-09-16 | — | — | US | disclosed |
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20250034150-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-01-30 | — | — | US | disclosed |
| CN-118804915-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| EP-0459244-B1 | Sulphonilised carboxylic acid amides | BAYER AG (DE) | 1996-02-28 | — | — | EP | disclosed |
| US-5256632-A | Pre- and postemergence | BAYER AKTIENGESELLSCHAFT (DE) | 1993-10-26 | — | — | US | disclosed |
| US-5205853-A | Premergence and postemergence herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| EP-0459244-A1 | Sulphonilised carboxylic acid amides | BAYER AG (DE) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | DPP4 3827/4885DPP8 3513/4885DPP7 2880/4885 |
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BTK, LYN, SYK | DPP4 4492/4885DPP8 3972/4885DPP7 3741/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | DPP4 2792/4885DPP8 2471/4885DPP7 2614/4885 |
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | DPP4 4122/4885DPP8 3959/4885DPP7 3860/4885 |
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | BTK, SYK, ABL1 | DPP4 2004/4885DPP8 2395/4885DPP7 2440/4885 |
| US-20250034150-A1 | BTK INHIBITORS | BTK, SYK, LYN | DPP4 3123/4885DPP8 3487/4885DPP7 2783/4885 |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | DPP4 822/4885DPP8 1787/4885DPP7 1950/4885 |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | ABL1, CDK1, CDK2 | DPP4 4817/4885DPP8 4812/4885DPP7 4639/4885 |
| US-20220389004-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, SYK, ABL1 | DPP4 2004/4885DPP8 2395/4885DPP7 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.